Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222260 · ClinicalTrials.gov registry record · Phase 2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
A Phase 2 study of AL Amyloidosis, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT01222260 is a Phase 2 study of AL Amyloidosis that has completed, run by Columbia University. The registered enrollment target is 40 participants, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT01222260, a Phase 2 study of AL Amyloidosis, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment, and to to estimate the partial hematologic response rate (PHR).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Bendamustine
Study Locations (6)
New York
- Mt. Sinai Medical Center - New York
- Columbia University - New York
- Memorial Sloan-Kettering Cancer Center - New York
Massachusetts
- Tufts Medical Center - Boston
- Boston Medical Center - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-01 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222260
The ClinicalTrials.gov registry entry for NCT01222260 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01222260 reports 6 study locations spanning 3 distinct geographic areas - top geographies include New York, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT01222260 about?
NCT01222260 is a clinical study titled "Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis". The study is being done to see if the combination of bendamustine and dexamethasone will help people with amyloidosis that has returned after standard treatment, and to to estimate the partial hematologic response rate (PHR).
What is the current status of trial NCT01222260?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2013-01. Estimated completion is 2019-07-03.
What conditions does trial NCT01222260 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT01222260?
The interventions under investigation include: Dexamethasone (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01222260?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01222260 being conducted?
This trial has 6 study locations across Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RECRUITING · Phase 2
-
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
ACTIVE NOT RECRUITING · Phase 2
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Ixazomib Maintenance Study in Patients With AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.